IPN Ipsen SA

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 47 - 2025

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 47 - 2025

Présentation agrégée par jour et par marché



Déclaration des transactions sur actions propres réalisées du 17 Novembre au 21 Novembre 2025
       
Nom de l'émetteurCode identifiant de l'émetteur (code LEI)Jour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre de titres)Prix pondéré moyen journalier d'acquisitionCode identifiant marché
IPSEN549300M6SGDPB4Z94P1117/11/2025FR0010259150 300 130,30000AQEU
IPSEN549300M6SGDPB4Z94P1117/11/2025FR0010259150 1 500 130,06667CEUX
IPSEN549300M6SGDPB4Z94P1117/11/2025FR0010259150 300 130,30000TQEX
IPSEN549300M6SGDPB4Z94P1117/11/2025FR0010259150 2 367 130,01234XPAR
IPSEN549300M6SGDPB4Z94P1118/11/2025FR0010259150 300 129,50000AQEU
IPSEN549300M6SGDPB4Z94P1118/11/2025FR0010259150 1 500 128,56667CEUX
IPSEN549300M6SGDPB4Z94P1118/11/2025FR0010259150 300 128,40000TQEX
IPSEN549300M6SGDPB4Z94P1118/11/2025FR0010259150 2 400 129,18213XPAR
IPSEN549300M6SGDPB4Z94P1119/11/2025FR0010259150 300 127,95733AQEU
IPSEN549300M6SGDPB4Z94P1119/11/2025FR0010259150 1 500 128,03333CEUX
IPSEN549300M6SGDPB4Z94P1119/11/2025FR0010259150 300 127,90000TQEX
IPSEN549300M6SGDPB4Z94P1119/11/2025FR0010259150 2 296 128,22757XPAR
IPSEN549300M6SGDPB4Z94P1120/11/2025FR0010259150 300 127,30000AQEU
IPSEN549300M6SGDPB4Z94P1120/11/2025FR0010259150 1 500 127,88000CEUX
IPSEN549300M6SGDPB4Z94P1120/11/2025FR0010259150 300 128,10000TQEX
IPSEN549300M6SGDPB4Z94P1120/11/2025FR0010259150 2 308 128,18982XPAR
IPSEN549300M6SGDPB4Z94P1121/11/2025FR0010259150 300 126,60000AQEU
IPSEN549300M6SGDPB4Z94P1121/11/2025FR0010259150 1 400 126,35000CEUX
IPSEN549300M6SGDPB4Z94P1121/11/2025FR0010259150 300 126,50000TQEX
IPSEN549300M6SGDPB4Z94P1121/11/2025FR0010259150 2 400 126,22213XPAR
    22 171 128.30045 

Pièce jointe



EN
25/11/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

4h / 25m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...

4h / 25m 1 EN
Free Trial
IPN IPSEN SA

Ipsen: 1 director

A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment

February 19, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publie ses comptes consolidés 2025

Ipsen S.A. publie ses comptes consolidés 2025 Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch